Effect Of Rosiglitazone On The Number Of Circulating Endothelial Progenitor Cells In Patients With Stable Coronary Artery Disease And Impaired Glucose Regulation

Objective:To observe the therapeutic efficacy of rosiglitazone on the number of circulating endothelial progenitor cells(EPCs)in patients with stable coronary artery disease and impaired glucose regulation (IGR).Methods: 60 consecutive patients with coronary artery disease and IGR were divided into study group and control group randomly. Both received conventional therapy, while study group (30 cases) added rosiglitazone 4mg/d for 12 weeks. Before and after intervention, metabolic parameters and C-reactive protein (CRP) were measured and circulating EPCs as measured by the number of CD133/kinase insert domain receptor (KDR) double positive cells were detected by FACS. Results: (1) Compared with basal value , after 12 weeks study group had a significant reduction in FPG,2hPG,FINS,HOMA - IR,CRP,TC,TG and LDL– C ,P<0.01;Control group had a reduction in FPG,2hPG,LDL– C and CRP, P<0.05;After 12 weeks both group had a increase in the number of circulating EPCs , P<0.05,While study group had a greater increase than control group, P<0.05;(2) In the study group ,improving value of circulating EPCs was negatively correlated with improving value of HOMA-IR,FINS,TC and LDL– C.Conclusion: Rosiglitazone improved insulin resistance and the metabolism of glucose and lipid, and increased the number of circulating EPCs in patients with coronary artery disease and IGR. The potential cardioprotective effect of rosiglitazone would benefit the patients with coronary artery disease and IGR.